Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD - US21900C3088 - Common Stock

12.4 USD
-0.4 (-3.12%)
Last: 9/5/2025, 8:06:01 PM
12.53 USD
+0.13 (+1.05%)
Pre-Market: 9/8/2025, 7:38:10 AM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to CRMD. CRMD was compared to 195 industry peers in the Pharmaceuticals industry. While CRMD has a great health rating, its profitability is only average at the moment. An interesting combination arises when we look at growth and value: CRMD is growing strongly while it also seems undervalued. These ratings would make CRMD suitable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

CRMD had positive earnings in the past year.
CRMD had a positive operating cash flow in the past year.
CRMD had negative earnings in each of the past 5 years.
CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With an excellent Return On Assets value of 20.25%, CRMD belongs to the best of the industry, outperforming 96.92% of the companies in the same industry.
With an excellent Return On Equity value of 23.19%, CRMD belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
The Return On Invested Capital of CRMD (17.64%) is better than 94.87% of its industry peers.
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROIC 17.64%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

CRMD has a Profit Margin of 42.11%. This is amongst the best in the industry. CRMD outperforms 97.44% of its industry peers.
CRMD has a better Operating Margin (40.60%) than 97.44% of its industry peers.
CRMD has a better Gross Margin (95.62%) than 97.44% of its industry peers.
In the last couple of years the Gross Margin of CRMD has grown nicely.
Industry RankSector Rank
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

CRMD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, CRMD has more shares outstanding
The number of shares outstanding for CRMD has been increased compared to 5 years ago.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CRMD has an Altman-Z score of 17.87. This indicates that CRMD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 17.87, CRMD belongs to the top of the industry, outperforming 94.36% of the companies in the same industry.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 17.87
ROIC/WACC1.77
WACC9.96%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 7.82 indicates that CRMD has no problem at all paying its short term obligations.
The Current ratio of CRMD (7.82) is better than 76.92% of its industry peers.
CRMD has a Quick Ratio of 7.52. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
CRMD has a better Quick ratio (7.52) than 75.90% of its industry peers.
Industry RankSector Rank
Current Ratio 7.82
Quick Ratio 7.52
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 180.65% over the past year.
The Revenue has grown by 14970.65% in the past year. This is a very strong growth!
The Revenue has been growing by 174.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
Revenue 1Y (TTM)14970.65%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%

3.2 Future

CRMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 55.63% yearly.
The Revenue is expected to grow by 58.84% on average over the next years. This is a very strong growth
EPS Next Y526.6%
EPS Next 2Y195.05%
EPS Next 3Y110.66%
EPS Next 5Y55.63%
Revenue Next Year443.89%
Revenue Next 2Y191.39%
Revenue Next 3Y112.4%
Revenue Next 5Y58.84%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 100M 200M 300M 400M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

CRMD is valuated correctly with a Price/Earnings ratio of 16.53.
CRMD's Price/Earnings ratio is rather cheap when compared to the industry. CRMD is cheaper than 85.13% of the companies in the same industry.
CRMD is valuated rather cheaply when we compare the Price/Earnings ratio to 27.06, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 5.60, which indicates a rather cheap valuation of CRMD.
95.38% of the companies in the same industry are more expensive than CRMD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.69. CRMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.53
Fwd PE 5.6
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 83.59% of the companies listed in the same industry.
CRMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRMD is cheaper than 80.51% of the companies in the same industry.
Industry RankSector Rank
P/FCF 30.44
EV/EBITDA 14.11
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

CRMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CRMD has a very decent profitability rating, which may justify a higher PE ratio.
CRMD's earnings are expected to grow with 110.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y195.05%
EPS Next 3Y110.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (9/5/2025, 8:06:01 PM)

Premarket: 12.53 +0.13 (+1.05%)

12.4

-0.4 (-3.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners34.07%
Inst Owner Change49.08%
Ins Owners1.08%
Ins Owner Change5.65%
Market Cap925.66M
Analysts81.54
Price Target20.23 (63.15%)
Short Float %20.49%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.96%
Min EPS beat(2)13.12%
Max EPS beat(2)58.8%
EPS beat(4)4
Avg EPS beat(4)44.57%
Min EPS beat(4)13.12%
Max EPS beat(4)58.8%
EPS beat(8)7
Avg EPS beat(8)23.17%
EPS beat(12)8
Avg EPS beat(12)15.69%
EPS beat(16)11
Avg EPS beat(16)13.24%
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)3.69%
Max Revenue beat(2)14.48%
Revenue beat(4)4
Avg Revenue beat(4)9.28%
Min Revenue beat(4)3.62%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.85%
PT rev (3m)27.96%
EPS NQ rev (1m)57.84%
EPS NQ rev (3m)107.21%
EPS NY rev (1m)36.84%
EPS NY rev (3m)72.88%
Revenue NQ rev (1m)38.3%
Revenue NQ rev (3m)50.09%
Revenue NY rev (1m)33.21%
Revenue NY rev (3m)48.84%
Valuation
Industry RankSector Rank
PE 16.53
Fwd PE 5.6
P/S 7.62
P/FCF 30.44
P/OCF 30.39
P/B 4.2
P/tB 4.23
EV/EBITDA 14.11
EPS(TTM)0.75
EY6.05%
EPS(NY)2.21
Fwd EY17.84%
FCF(TTM)0.41
FCFY3.29%
OCF(TTM)0.41
OCFY3.29%
SpS1.63
BVpS2.96
TBVpS2.93
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROCE 22.33%
ROIC 17.64%
ROICexc 129.11%
ROICexgc 137.01%
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
FCFM 25.03%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score7
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 10.02%
Cap/Sales 0.04%
Interest Coverage 1343.8
Cash Conversion 61.11%
Profit Quality 59.44%
Current Ratio 7.82
Quick Ratio 7.52
Altman-Z 17.87
F-Score7
WACC9.96%
ROIC/WACC1.77
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
EPS Next Y526.6%
EPS Next 2Y195.05%
EPS Next 3Y110.66%
EPS Next 5Y55.63%
Revenue 1Y (TTM)14970.65%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%
Revenue Next Year443.89%
Revenue Next 2Y191.39%
Revenue Next 3Y112.4%
Revenue Next 5Y58.84%
EBIT growth 1Y184.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year489.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y197%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.89%
OCF growth 3YN/A
OCF growth 5YN/A